Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia

Roland B. Walter, Laura C. Michaelis, Megan Othus, Geoffrey L. Uy, Jerald P. Radich, Richard F. Little, Sandi Hita, Lalit Saini, James M. Foran, Aaron T. Gerds, Heidi D. Klepin, Annette E. Hay, Sarit Assouline, Jeffrey E. Lancet, Stephen Couban, Mark R. Litzow, Richard M. Stone, Harry P. Erba

Research output: Contribution to journalLetter

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)E49-E52
JournalAmerican journal of hematology
Volume93
Issue number2
DOIs
StatePublished - Feb 1 2018

ASJC Scopus subject areas

  • Hematology

Cite this

Walter, R. B., Michaelis, L. C., Othus, M., Uy, G. L., Radich, J. P., Little, R. F., Hita, S., Saini, L., Foran, J. M., Gerds, A. T., Klepin, H. D., Hay, A. E., Assouline, S., Lancet, J. E., Couban, S., Litzow, M. R., Stone, R. M., & Erba, H. P. (2018). Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. American journal of hematology, 93(2), E49-E52. https://doi.org/10.1002/ajh.24980